# A Study of Orforglipron (LY3502970) in Chinese Participants With Obesity or Overweight and Weight-Related Health Problems

Clinical trial · Eli Lilly and Company

- Archive id: nct:NCT07790861
- Published: 2026-08-27
- Venue: ClinicalTrials.gov
- ClinicalTrials.gov: https://clinicaltrials.gov/study/NCT07790861
- Source URL: https://clinicaltrials.gov/study/NCT07790861
- Provenance: clinicaltrials

## Abstract

The purpose of this study is to learn how well orforglipron works and how safe it is in Chinese adults with obesity or overweight and related health problems. Participation in this study will last about 53 weeks (about 1 year).

_Abstract reproduced under ClinicalTrials.gov (U.S. National Library of Medicine), data processed 2026-10-29T09:00:05; modifications: selected fields only; whitespace normalized; brief summary truncated to 2,000 characters._

## Trial details

- acronym: ATTAIN-CN
- status: NOT_YET_RECRUITING
- phase: PHASE3
- study type: INTERVENTIONAL
- enrollment: 192
- sponsor: Eli Lilly and Company
- conditions: Obesity; Overweight
- interventions: DRUG: Orforglipron; DRUG: Placebo
- start date: 2026-12-01
- start date type: ESTIMATED
- primary completion date: 2028-03-01
- has results: false
- data source: ClinicalTrials.gov
- data processed: 2026-10-29T09:00:05
- modifications: selected fields only; whitespace normalized; brief summary truncated to 2,000 characters

Topics: [GLP-1 & Incretin Therapies](https://space-kitty.com/topics/glp1-metabolic)

---
Space Kitty Archive · https://space-kitty.com · API: https://space-kitty.com/api/v1 · MCP: https://space-kitty.com/mcp · Premium: $0.20/request via x402 (Base Sepolia (testnet)). Metadata: arXiv (CC0), OpenAlex (CC0), Europe PMC (CC BY/CC0 works), ClinicalTrials.gov.